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Abstract
Context—High blood pressure is an important risk factor for cardiovascular disease (CVD) and 
stroke, the leading cause of death in the U.S. and a substantial national burden through lost 
productivity and medical care. A recent Community Guide systematic review found strong 
evidence of effectiveness of team-based care in improving blood pressure control. The objective 
of the present review was to determine from the economic literature whether team-based care for 
blood pressure control is cost-beneficial and/or cost-effective.
Evidence acquisition—Electronic databases of papers published January 1980 – May 2012 
were searched to find economic evaluations of team-based care interventions to improve blood 
pressure outcomes, yielding 31 studies for inclusion.
Evidence synthesis—In analyses conducted in 2012, intervention cost, healthcare cost averted, 
benefit-to-cost ratios, and cost-effectiveness were abstracted from the studies. The quality of 
estimates for intervention and healthcare cost from each study were assessed using three elements: 
intervention focus on blood pressure control; incremental estimates in the intervention group 
relative to a control group; and inclusion of major cost-driving elements in estimates. Intervention 
cost per unit reduction in systolic blood pressure was converted to lifetime intervention cost per 
quality-adjusted life-year (QALY) saved using algorithms from published trials.
Conclusion—Team-based care to improve blood pressure control is cost-effective based on 
evidence that 26 of 28 estimates of $/QALY gained from 10 studies were below a conservative 
threshold of $50,000. This finding is salient to recent health care reforms in the U.S. and 
coordinated patient-centered care through formation of Accountable Care Organizations (ACOs).
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High blood pressure presents a substantial economic burden in the U.S., fueled by increased 
medical expenditures, reduced worksite productivity from associated absences, and 
premature death. Recent U.S. studies estimate annual costs at $47.5 billion in direct medical 
expenses and $3.5 billion in lost productivity.1 High blood pressure is an important risk 
factor for cardiovascular disease (CVD) and stroke: the 2014 statistical update from the 
American Heart Association estimated that CVD and stroke cost $193.4 billion in medical 
care and about $122 billion in lost productivity from premature death in 2010.2
The objective of this review was to determine whether team-based care (TBC) for blood 
pressure (BP) control is cost-beneficial and/or cost-effective. Briefly, in TBC, a nurse, 
pharmacist, and/or other healthcare personnel work together with a provider and patient to 
manage the patient’s care. A recent Community Guide systematic review3 found strong 
evidence that TBC improves BP control. This paper provides estimates of intervention cost, 
healthcare cost averted, productivity gains, and health effects associated with TBC 
interventions to improve BP control. These estimates are crucial for understanding the 
economic merits of TBC.
Evidence Acquisition
General methods for Community Guide systematic economic reviews are available at 
www.thecommunityguide.org/about/economics.html. Methods specific to the present review 
are detailed below.
A systematic review team (the team) was constituted, including subject matter experts on 
CVD from various agencies, organizations, and academic institutions together with qualifıed 
systematic reviewers from The Community Guide branch at CDC. The team worked under 
the oversight of the Community Preventive Services Task Force.
Conceptual Approach
Team-based care to improve BP control is a health systems-level, organizational 
intervention that incorporates a multidisciplinary team to improve the quality of 
hypertension care for patients. The team comprises the patient, the patient’s primary care 
provider, and other professionals who support and share the responsibilities of hypertension 
care including medication management, patient follow-up, and adherence and self-
management. The complete definition is at www.thecommunityguide.org/cvd/
RRteambasedcare.html. TBC is usually implemented in private or public healthcare settings, 
and is likely to be financed by healthcare organizations or covered by insurers. Thus, 
evaluation studies may take a healthcare system perspective that only considers costs and 
benefits of TBC related to the healthcare delivery system. Because the healthcare system 
perspective and the broader societal perspective are each useful ways to assess economic 
effects of TBC, both perspectives were considered in this review.
Appropriate study design and measurement are important in identifying the true economic 
effect of an intervention, an important element of which is the use of a control group. 
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Therefore, studies that included a control group and those in which the control group 
received usual care or treatment are identified.
Intervention cost is the monetized value of labor and non-labor resources needed to 
implement and maintain TBC to improve BP control; it reflects the incremental cost of TBC 
beyond the cost of usual care. The components of intervention cost are the cost of provider 
time, patient time, and rent and utilities.
The impact of TBC on healthcare cost is the difference in cost of healthcare products and 
services used by the intervention group and by the control group or the pre to post change 
where there is no control group. The components of healthcare cost are outpatient visits, 
medications, hospital inpatient stays, emergency room visits, and patient-time.
Effective TBC interventions to control BP lead to reduced systolic and diastolic blood 
pressure (SBP and DBP, respectively) and increase the number of patients achieving BP 
control. The reduction in BP, in turn, reduces morbidity and mortality and increases the 
quantity and quality of years lived, measured as quality-adjusted life-years (QALYs).
The expected economic benefit of TBC is the sum of savings from averted healthcare cost 
and the increased productivity of patients at their worksites owing to reduced morbidity and 
mortality. Cost-benefit analysis compares economic benefit to intervention cost, where both 
benefit and cost are monetized and expressed in dollar terms; an intervention is cost-
beneficial when economic benefit exceeds intervention cost.
The ratio of intervention cost to QALY gained produces cost-utility, a type of cost-
effectiveness assessment: an intervention is cost-effective when cost per QALY gained is 
less than a conservative threshold of $50,000.4 Because the threshold is based on net cost 
(intervention cost plus healthcare cost) per QALY gained, an additional set of estimates of 
net cost per QALY gained is also computed. This review defines other cost-effectiveness 
measures based on additional health outcomes: intervention cost per unit reduction in BP ($/
mmHg) and intervention cost per additional person achieving BP control. Interventions 
targeting BP control can be readily compared to each other based on results expressed as 
cost per unit reduction in BP or additional person achieving BP control. Results expressed as 
cost per QALY gained facilitate comparison of interventions to control BP with other health 
interventions.
For studies that reported an intermediate health outcome, such as reduction in SBP, along 
with the cost of intervention, reductions in SBP were converted to QALY gained using 
existing algorithms to allow estimation of cost per QALY gained. A comprehensive registry 
of cost-effectiveness studies on a wide variety of diseases and treatments was searched to 
identify studies that translated SBP to QALY (research.tufts-nemc.org/cear4/).5 Two search 
terms were used—BP/hypertension and QALY—so that the yield would be broadly 
inclusive. Review of titles and abstracts from 44 papers and further review of full text of 15 
studies identified two studies6,7 that converted a reduction in SBP to QALY gained. Both 
studies were for populations with diabetes. The present review adopted the two conversion 
algorithms used in the studies.
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This first reference study6 assumed that a 5.7 mmHg reduction in SBP sustained over a 
lifetime would result in a gain of 0.53 QALYs, where QALY/mmHg=0.093. The translation 
in this study conducted in the United Kingdom was based primarily on results from the UK 
Prospective Diabetes Study (UKPDS: www.dtu.ox.ac.uk/ukpds/), which followed a group of 
adults (mean age: 56 years) with diabetes over a period of 8 years. Risk of myocardial 
infarction and stroke were incorporated based on both UKPDS8 and on the Framingham 
Heart Study9–11 with weights for QALY drawn from the CDC Diabetes Cost-Effectiveness 
Study Group.12 The second reference study7 demonstrated that each unit reduction in mmHg 
of SBP is associated with approximately 0.009 QALYs gained during each annual cycle of a 
simulation model. This study modeled the experience of a cohort of people with diabetes 
aged 20–74 years (mean age ~52 years) over 20 years. Risks of myocardial infarction, 
stroke, peripheral artery disease, end stage renal disease, and severe visual loss were drawn 
from the UKPDS13–15 and the Framingham Heart Study,9 with QALY based on patient 
reported quality-of-life.16 The QALY gained per unit reduction in SBP in the two studies is 
not far apart, considering that the second study was focused on a slightly younger cohort and 
based on patient-reported quality of life.
Cost and economic benefit estimates from included studies were standardized to a per 
person per year basis when possible. All monetary values were then converted to 2010 U.S. 
dollars; the Consumer Price Index from the Bureau of Labor Statistics (www.bls.gov/cpi/
tables.htm) was used to adjust for inflation and Purchasing Power Parity indices from the 
World Bank (data.worldbank.org/indicator/PA.NUS.PRVT.PP) to convert from foreign 
currencies. Considerable variability may remain, owing to various factors including 
composition of the team providing the care, allocation of activities among team members, 
and incomplete accounting for costs and benefits associated with the intervention. The major 
elements that drive intervention costs and benefits were identified a priori based on 
knowledge and information gained from peer-reviewed literature and subject matter experts. 
Finally, what variability remained was acknowledged by presenting medians of individual 
estimates with interquartile intervals.
Team-based care interventions that go beyond BP control, with additional objectives such as 
treatment of hyperlipidemia and hyperglycemia, are likely to cost more to implement than 
interventions focused on BP control, and also likely to avert greater healthcare cost when 
they are effective. Separate estimates are provided in this paper from the full set of studies 
and from the studies of TBC interventions that focused on BP control.
Search Strategy and Search Yield
Included studies came from two separate searches. First, a broad search for economic studies 
of interventions that focused on BP control was conducted by CDC’s Division for Heart 
Disease and Stroke Prevention (DHDSP), from January 1985 to March 2012. Databases 
searched were OVID/Medline, EMBASE, PsycINFO, CINAHL, Sociological Abstracts, 
Web of Science, Cochrane, and EconLit. The search strategy used by DHDSP is available at 
www.thecommunityguide.org/cvd/supportingmaterials/SS-team-based-care-econ.html. 
Authors screened 9,152 titles from the DHDSP search for TBC intervention studies with 
economic outcomes, based on the conceptual approach for this review. In addition, any 
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studies with economic information identified in the search for the review of TBC 
effectiveness3 were also included. That search strategy is available at 
www.thecommunityguide.org/cvd/supportingmaterials/SS-team-based-care.html. Screening 
from these two sources resulted in 31 included studies (Figure 1), where studies were 
included in the present review if they:
• met the intervention definition;
• were in English;
• were implemented in a high-income economy;
• reported the economic cost or economic benefit of the intervention;
• had BP control as the primary intervention focus; and
• did not include populations with secondary hypertension.
Evidence Synthesis
Table 1 provides an overview of four characteristics of included studies: location, setting, 
presence of control group, and period of publication. Details of the included studies are 
available at www.thecommunityguide.org/cvd/supportingmaterials/SETecon-Team-Based-
Care.pdf. Table 2 summarizes the type of economic analyses conducted in included studies.
Intervention Cost
This review identified three components of cost to implement TBC interventions: provider 
time, patient time, and rent and utilities. Studies that reported including two or more 
components provided “reasonably complete” accounting of intervention cost.
Table 3 shows the components included in the estimates of intervention cost reported in 20 
included studies6,17–35; two studies26,33 measured it as the post minus pre cost for the 
intervention group; the remaining studies measuring it as the incremental cost over usual 
care. Confidence in the estimates was enhanced because most studies included important 
components of intervention cost and appropriately measured incremental cost. Further, the 
present review calculated medians and interquartile intervals to draw attention to the central 
tendency rather than to the range.
Table 4 summarizes estimates for intervention cost per person per year from the included 
studies. Based on 29 observations from 20 studies, the median intervention cost of TBC was 
$284 per person per year (interquartile interval [IQI]: $153 to $670). The median 
intervention cost was $359 for studies6,17,20–22,24,25,27,28,30,34 that were reasonably 
complete in their accounting of intervention cost, $198 per person per year for 
studies17–22,27,28,31,33,34 that focused solely on BP, and $225 for studies17,20–22,27,28,34 with 
both features. The cost of intervention was smaller where the focus was on BP control 
compared to interventions with one or more additional objective(s).
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Impact on Healthcare Cost
Five components of healthcare cost were identified for analysis of the impact of TBC: 
outpatient visits, hospital inpatient stays, emergency room visits, medications, and patient 
time. The accounting of healthcare cost was considered reasonably complete when studies 
included three or more of these components. Table 5 shows the 20 studies17,22,24,27–29,32–45 
that reported the components included in estimates for cost of healthcare, with more than 
half of the studies including at least three components. Five studies24,29,38,40,42 measured 
the change as post intervention healthcare cost minus pre for the intervention group; the 
remaining studies measured it as the incremental healthcare cost experienced by the 
intervention group over that experienced by the control group.
Table 6 summarizes estimates of healthcare cost impacts associated with the TBC 
intervention. One study46 reported cost per person per year to be $4,316 higher for the 
intervention group compared to usual care. This was considered an outlier and not included 
in Table 6 because the TBC involved post-acute home-based care of high-risk patients. 
Across 23 observations of healthcare cost impacts from 20 studies, the median was $65 per 
person per year (IQI: –$235 to $318). Ten of the estimates from 10 
studies17,24,35,36,38,40–43,45 were negative, indicating healthcare cost savings. With the focus 
on 11 studies17,22,24,27,28,33,35,36,38,41,42 that provided reasonably complete accounting, the 
median was a healthcare cost saving of $77 per person per year (IQI: –$436 to $98). 
Seven17,24,35,36,38,41,42 of these studies reported estimated healthcare cost-savings from 
TBC.
Overall, evidence for TBC reducing healthcare cost was mixed, though most (64%) 
studies17,24,35,36,38,41,42 with a reasonably complete accounting of healthcare cost 
components indicated that TBC resulted in healthcare cost savings (Table 6).
For seven studies17,27,28,32–35 that reported both intervention cost and healthcare cost, the 
sum of the costs was computed as an estimate of the total cost of TBC, producing a median 
cost per person per year of $329 (IQI: $190 to $658).
Cost Per Unit Reduction of Blood Pressure and Cost Per Additional Person with 
Controlled Blood Pressure
Ten studies18,20,21,23,25,29,30,33–35 with 14 pairs of observations of intervention cost and 
reduction in SBP showed a median cost per unit of mmHg reduction in SBP of $87 (IQI: 
$52 to $202; Table 7). The median cost-effectiveness of TBC in reducing DBP was $102 per 
unit (IQI: $51 to $123) based on 11 observations from nine studies.18,20,23,27–30,33,35 The 
health benefit from reduced BP is very likely positive for SBP/DBP ≤140/90 as 
recommended by JNC-7 (www.nhlbi.nih.gov/health-pro/guidelines/current/hypertension-
jnc-7) and previous studies have shown that the benefit becomes minimal for SBP and DBP 
below certain thresholds.47 A positive intervention cost and no possibility of health benefit 
from reducing BP below these thresholds warrants further comment. Of ten studies, the 
mean SBP after the effect of intervention was >140 in three studies,18,23,29 115–140 in 
seven studies,20,21,25,30,33–35 and <115 in no studies. Of nine studies, the mean DBP after 
the effect of intervention was >90 for two studies,27,28 70–90 in six studies,18,23,29,30,33,35 
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and at 68.8 in one study.20 Based on these means, it is likely that the reductions achieved in 
SBP/DBP from the interventions in this review fell within the beneficial range.
Several studies reported the incremental percentage of people in the TBC intervention group 
who achieved controlled BP. This measure of impact is important from a public health and 
healthcare organization perspective because it provides a reading on population status with 
respect to uncontrolled BP. (Table 8 shows cost-effectiveness derived from this outcome.) 
The median incremental cost per additional person achieving BP control was $3,316 (IQI: 
$2,047 to $5,422), based on 16 observations from 11 studies.6,19–24,28,30,34,35 The thresholds 
for BP control were DBP<90 in two studies19,28 from the 1980s, SBP/DBP<140/80 in one6 
based on a diabetic population , and SBP/DBP<140/90 in the others. The cost per additional 
person achieving BP control may appear large in comparison to the median intervention cost 
or the cost per unit of BP reduction. However, two factors should be considered. First, it is 
the cost per additional person achieving BP control compared to usual care. Second, the 
intervention is not 100% effective and only part of the intervention group will achieve BP 
control. For example, even a large reduction in SBP starting from a high baseline may not 
indicate controlled BP.
Cost-Benefit Studies and Cost-Utility Studies
Cost-benefit or cost per QALY outcomes are needed to draw conclusions on the economic 
value of an intervention. Few included studies reported these outcomes: two studies17,24 
reported benefit-to-cost ratios, two22,34 provided cost per life year saved, and one6 estimated 
cost per QALY gained.
Cost-benefit studies—Two studies reported the ratio of the monetized value of 
intervention benefit to intervention cost as 12.1:124 and 10:1,17 respectively, indicating that 
TBC was cost-saving, but several caveats apply. The first study24 had multiple objectives 
beyond BP control, and healthcare cost estimates were for patients selected from a pool of 
high utilizers. The second study17 underestimated the cost of software development and 
deployment by simply dividing the fixed cost from the trial by the much larger number of 
people with high BP in the Quebec region, without considering issues of scalability.
Cost-effectiveness studies—One study6 reported a cost per QALY of $4,763, which is 
far below the $50,000 threshold for cost-effectiveness. The estimate was based partly on 
measurements of intervention cost and SBP reduction from an actual intervention; modeling 
of QALYs saved was based on the relationship between observed reduction in SBP and 
QALYs saved from a large population-based RCT.
Two other cost-effectiveness studies reported cost per life year saved, one22 ranging from 
$48,995 to $100,744 and the other34 from $23,299 to $64,832. Finally, another study29 
reported the cost of TBC in terms of observed averted health events, namely $64,610 per 
cardiovascular event averted and $118,873 per chronic heart disease event averted. There is 
no standard threshold against which to compare these estimates of cost per averted health 
events to reach a determination about their economic value.
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Cost-effectiveness studies (cost per QALY): SBP to QALY converted studies
—Ten included studies provided estimates for reductions in SBP but did not evaluate the 
long-term effects on morbidity and mortality. The team translated these results into two sets 
of cost-effectiveness estimates based on formulae relating SBP reduction to QALY gained 
in two reference studies.6,7
Fourteen observations of SBP reductions from the ten included 
studies18,20,21,23,25,29,30,33–35 were converted to QALYs (Table 9), with associated 
intervention costs discounted at 3% and summed over a 20-year expected lifetime. Applying 
the method from one of the reference studies6 to these data resulted in an estimated median 
cost per QALY gained of $13,992 (IQI: $8,339 to $32,292). Two observations from one 
study21 produced estimates that were above the conservative cost-effectiveness threshold of 
$50,000 per QALY, with one just over $50,000 and one just under $60,000. Applying the 
formula from the second reference study7 to the same data resulted in a median estimated 
cost per QALY gained of $9,716 (IQI: $5,791 to $22,425). Based on this formula, all 14 
observations produced estimates that were below the threshold. Keeping in mind that the 
$50,000 threshold is based on intervention cost plus the change in healthcare cost, an 
additional set of estimates for net cost per QALY gained was derived for three studies33–35 
that reported intervention cost, healthcare cost, and reduction in SBP. Net cost per QALY 
gained estimates were $3,641,33 $37,071,34 and $5,49135 based on the method of the first 
reference study6 and $2,529,33 $25,744,34 and $3,81335 based on the second reference 
study.7
Several characteristics of the interventions were explored as explanatory variables for the 
variation observed in cost per QALY gained: implementation in a health system or 
community setting, type of team member added to usual care, management of medication, 
compared to usual care or not, and whether the baseline SBP was high or low relative to the 
140 threshold. All the studies included medication management and/or medication 
counseling. All studies had a control group that received usual care and all but two18,35 were 
implemented in healthcare settings. The results of the categorical analyses based on the 
remaining variables are presented in Table 9. It may appear that teams that added 
pharmacists and others had lower cost per QALY gained than those that added nurses. 
However, this difference in cost-effectiveness may also be explained by different baseline 




Evidence of cost per QALY gained from this economic review indicates that TBC is cost-
effective in improving BP control.
Discussion
The major caveat in this review is that the formulae for the relationship between SBP and 
QALY were drawn from the experience of people with diabetes and comorbid high BP. It is 
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not clear whether, and to what extent, limitation to people with diabetes leads to an 
overestimation or underestimation of the relationship between SBP and QALYs; even 
though it is possible that the overall QALY may be worse for diabetic patients compared to 
hypertensive patients, the relative impact of SBP reduction on the overall QALY of diabetic 
patients compared to that of hypertensive patients is uncertain.
The cost of intervention and the impact on healthcare cost are key estimates reported in the 
included studies from which the present review drew findings about cost-effectiveness and 
the cost impact of TBC on utilization of healthcare resources. The studies varied in 
completeness of accounting for components of these costs and in whether the increment in 
cost was measured relative to a control group. Despite these variations, the finding of cost-
effectiveness is credible given that most studies were reasonably complete in accounting for 
components of intervention cost and all but two of the 28 cost per QALY estimates were 
below the conservative $50,000 threshold. Net cost per QALY saved could be calculated 
only for 3 studies, but all three estimates were below the conservative threshold of $50,000.
The generalizability of the review’s results to practice is not seamless because a substantial 
proportion of the evidence is drawn from studies implemented in research settings. Also, the 
review’s overall cost-effectiveness conclusion is based on modeled long-term outcomes. The 
incentives and protocols that bound provider and patient together as a collaborative team in 
research must be replicated or replaced with alternatives to implement the intervention in 
practice. Hence, multiple reimbursement systems (e.g., for pharmacy and medical benefits) 
will have to be coordinated and new services and providers may also have to be added to 
reimbursement systems. The change necessary in the organization, delivery, and 
reimbursement for care is feasible and sustainable, as demonstrated by the success of the 
Kaiser Permanente Northern California hypertension program.48
By extrapolating reductions in BP found in trials to 20-year horizons of QALY gained, the 
present review implicitly assumed that the TBC intervention is sustained and paid for over 
the same period. Over this long term, members of the team must receive compensation to 
ensure their continued participation. From a financial standpoint, the insurers/payers must 
find it in their interest to make a long-term commitment to support these teams and to pay 
individual providers, some of whom they had not dealt with directly. Arrangements by 
health plans to reimburse teams were far from prevalent during the periods covered in the 
included studies. In contrast, recent health care reform in the U.S. and the Affordable Care 
Act may promote TBC through Accountable Care Organizations (ACOs) by encouraging the 
formation of patient-centered teams and improving care coordination among clinicians.49,50
Finally, it may be argued that individuals don’t stay in health plans long enough for the 
plans to reap the financial benefits of some types of prevention,51 but members with high BP 
are well-served by TBC to bring their BP under control and manage any relapse.
Evidence Gaps
More complete and comprehensive reporting of cost and its components is needed. Some 
evaluation studies simply reported an aggregate estimate for intervention cost or healthcare 
cost without discussing the components. Many evaluations reported the aggregate estimate 
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and listed the components but did not provide values for the components, precluding an 
analysis of which components contributed the most to the aggregate estimate. An analysis of 
the components of cost or benefit reported in a body of evaluation studies would provide the 
data to determine what should be considered drivers of the estimated values.
More research is needed to see how variations in the TBC model (i.e., that employ different 
methods of patient engagement through differences in team structure and team activities) 
affect intervention cost and cost-effectiveness.
Associated costs of the intervention were not always reported. A number of studies reported 
only healthcare cost impact, probably with the objective of determining if TBC is healthcare 
cost-saving. However, a determination about economic value could not be drawn from these 
studies because the associated costs of intervention were not reported.
No evaluation study considered the impact of TBC on improved productivity at work. This 
review noted the omission of productivity considerations from intervention evaluations 
despite the fact that the magnitude of productivity losses attributable to CVD and stroke by 
themselves is highlighted in the burden literature.
Finally, a major gap in the economic evaluation literature for BP control is lack of a widely 
accepted standard relating reduced BP to QALY for the general population of people with 
high BP.
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Flow diagram: number of studies identified, reviewed in full text, reasons for exclusion, and 
total number of included studies. (CG, Community Guide; DHDSP, Division for Heart 
Disease and Stroke Prevention, CDC; TBC, team-based care)
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Table 1
Characteristics of Included Studies and Proportion of Studies Within Each Characteristic









Control group No control group 529,31,38,40,42
(16%)












VA, U.S. Department of Veterans Affairs
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Table 2
Included Studies by Type of Economic Analysis
Type of economic analysis Number of Studies
Intervention cost 206,17–35
Healthcare cost 2117,22,24,27–29,32–46
Both intervention and healthcare cost 717,27,28,32–35
Cost-benefit or Net benefit 217,24
Cost effectiveness Cost per mmHg SBP reduced 1018,20,21,23,25,29,30,33–35
Cost per mmHg DBP reduced 918,20,23,27–30,33,35
Cost per additional person
achieving BP control
116,19–24,28,30,34,35
Cost per life year saved 222,34
Cost per QALY gained 16
BP, blood pressure; DBP, diastolic blood pressure; QALY, quality-adjusted life year; SBP, systolic blood pressure
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Table 3
Intervention Cost: Components








Artinian 200118 Y — — 1
Bertera 198119 Y — — 1
Bosworth 2009b20 Y — Y 2
Bosworth 201121 Y — Y 2
Cote 200317 Y Y — 2
Datta 201022 Y — Y 2
Edelman 201023 Y — — 1
Isetts 200824 Y — Y 2
Katon 201025 Y — Y 2
Litaker 200326 Y — — 1
Logan 198127 Y Y Y 3
Logan 198328 Y Y — 2
Lowey 200729 Y — — 1
Ma 200930 Y — Y 2
Mason 20056 Y — Y 2
McGhee 199431 Y Y — 2
Munroe 199732 — — — NR
Okamoto 200133 Y — — 1
Reed 201034 Y Y Y 3
Wertz 201235 — — — NR
Total 18 5 9
NR, not reported; Y, yes
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Table 4
Intervention Cost per Person per Year





















Median (IQI) $284 (IQI: $153
to $670)
$359 (IQI: $198 to
$722)





Components of intervention cost were provider time, patient time, and rent and utilities.
BP, blood pressure; IQI, interquartile interval
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Table 6
Healthcare Cost Impact per Person per Year













































Components of healthcare cost were for outpatient visits, medications, hospital inpatient stays, emergency room (ER) visits, and patient time.
BP, blood pressure; IQI, interquartile interval
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Table 7
Cost-effectiveness of Reducing Systolic and Diastolic Blood Pressure, Measured as Cost per Millimeter of 
Mercury
Systolic BP Diastolic BP
All studies Studies with only
BP focus and ≥2
components of
intervention costa
All studies Studies with only


























Components of intervention cost were for provider time, patient time, and rent and utilities.
BP, blood pressure; IQI, interquartile interval; NA, not applicable
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Table 8
Cost-effectiveness per Additional Person Achieving Blood Pressure Controla
All studies
Studies with only BP focus








Median (IQI) $3316 (IQI: $2047 to
$5422)
$5327 (IQI: $2046 to
$7154)
a
Thresholds for BP control : two19,28 studies from the 1980s were based on DBP<90, one6 based on SBP/DBP<140/80 for a diabetic population , 
and the remaining were based on SBP/DBP<140/90.
b
Components of intervention cost were provider time, patient time, and rent and utilities.
BP, blood pressure; IQI, interquartile interval
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Table 9
Cost per QALY Gained Based on Conversion of Reduced SBP Attributable to Intervention





















$13,992 (IQI: $8339 to $32,292) $9,716 (IQI: $5791 to $22,425)
    Type of team
member added
    Nurse18,20,21,25,30,34 $24,042 (IQI: $8836 to $44,752) $16,696 (IQI: $6136 to
$31,077)
    Pharmacist and
Other23,29,30,33,35
$10,244 (IQI: $1934 to $13,992) $7114 (IQI: $1343 to $9716)
    Baseline SBP
    >14018,23,29,33 $5587 (IQI: $1334 to $9693) $3880 (IQI: $927 to $6731)
    ≤14020,21,25,30,34,35 $20,564 (IQI: $11,381 to $41,826) $14,280 (IQI: $7903 to
$29,045)
IQI, interquartile interval; QALY, quality-adjusted life years; SBP, systolic blood pressure
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